Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a biopharmaceutical company based in Stoughton, Massachusetts. Founded in 2014, it focuses on developing and commercializing medications for serious medical conditions, particularly chronic pain and attention deficit hyperactivity disorder (ADHD). The company employs around 357 people and reported significant revenue and net income. Collegium specializes in innovative drug delivery technologies, notably its proprietary DETERx platform, which allows for extended-release formulations with abuse-deterrent properties. Key products include Xtampza ER, an abuse-deterrent oxycodone for chronic pain, and the Nucynta portfolio, which offers both extended-release and immediate-release options for pain management. Other products include Belbuca for severe pain, Jornay PM for ADHD, and Symproic for opioid-induced constipation. The company is committed to responsible opioid stewardship and community health initiatives, aiming to improve well-being while addressing unmet needs in pain management and ADHD treatment.